Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682472 | 0.86 | GPR35 (0.48) | CCR2CACNA1BPLA2G4ALTB4RLTB4R2 | |
| SCHEMBL6002257 | 0.85 | CACNA1B (0.48) | CCR2CACNA1BKDM4EALDH1A1 | |
| SCHEMBL7677750 | 0.84 | PLA2G4A (0.49) | CCR2CACNA1BPLA2G4ALTB4RLTB4R2 | |
| SCHEMBL3958982 | 0.83 | CCR2 (0.56) | CCR2PLA2G4ALTB4RLTB4R2GPR35 | |
| SCHEMBL7681815 | 0.83 | CCR2 (0.55) | CCR2CACNA1BPLA2G4ALTB4RLTB4R2 | |
| SCHEMBL7679772 | 0.81 | ACSS2 (0.45) | CCR2CACNA1BPLA2G4ALTB4RLTB4R2 | |
| SCHEMBL7677561 | 0.81 | GPR35 (0.44) | CCR2CACNA1BPLA2G4ALTB4RLTB4R2 | |
| SCHEMBL7684946 | 0.79 | NTRK1 (0.52) | CCR2CACNA1BPLA2G4ALTB4RLTB4R2 | |
| SCHEMBL7679776 | 0.78 | CACNA1B (0.40) | CCR2CACNA1BPLA2G4ALTB4RLTB4R2 | |
| SCHEMBL5677246 | 0.78 | CCR2 (0.43) | CCR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |